BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27989824)

  • 1. Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testing.
    Tonon F; Zennaro C; Dapas B; Carraro M; Mariotti M; Grassi G
    Int J Pharm; 2016 Dec; 515(1-2):583-591. PubMed ID: 27989824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects.
    Scaggiante B; Farra R; Dapas B; Baj G; Pozzato G; Grassi M; Zanconati F; Grassi G
    Int J Pharm; 2016 Jun; 506(1-2):268-79. PubMed ID: 27094354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
    Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
    Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H; Ong R; Soo KC
    Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening.
    Jung DW; Oh ES; Park SH; Chang YT; Kim CH; Choi SY; Williams DR
    Mol Biosyst; 2012 Jul; 8(7):1930-9. PubMed ID: 22569777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6.
    Farra R; Dapas B; Pozzato G; Giansante C; Heidenreich O; Uxa L; Zennaro C; Guarnieri G; Grassi G
    Biochimie; 2010 May; 92(5):455-63. PubMed ID: 20144681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
    Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
    Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.
    Lim JJ; Hooi L; Dan YY; Bonney GK; Zhou L; Chow PK; Chee CE; Toh TB; Chow EK
    J Exp Clin Cancer Res; 2022 Aug; 41(1):249. PubMed ID: 35971164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma.
    Li M; Pathak RR; Lopez-Rivera E; Friedman SL; Aguirre-Ghiso JA; Sikora AG
    J Vis Exp; 2015 Oct; (104):. PubMed ID: 26484588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy.
    Liu YM; Xia Y; Dai W; Han HY; Dong YX; Cai J; Zeng X; Luo FY; Yang T; Li YZ; Chen J; Guan J
    BMC Cancer; 2014 Nov; 14():889. PubMed ID: 25429777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
    Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
    J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.
    Nakao K; Tanaka S; Miura T; Sato K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
    Cancer Sci; 2015 Aug; 106(8):1016-22. PubMed ID: 26011703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Auphen and dibutyryl cAMP suppress growth of hepatocellular carcinoma by regulating expression of aquaporins 3 and 9 in vivo.
    Peng R; Zhao GX; Li J; Zhang Y; Shen XZ; Wang JY; Sun JY
    World J Gastroenterol; 2016 Mar; 22(12):3341-54. PubMed ID: 27022216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of acriflavine in human hepatocellular carcinoma cells.
    Lee CJ; Yue CH; Lin YY; Wu JC; Liu JY
    Anticancer Res; 2014 Jul; 34(7):3549-56. PubMed ID: 24982368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.